Funding Opportunities

In 2021, GemPharmatech continues to call for applications from academia and not-for-profit organizations for “The GEMMs for Rare Disease Research Initiative” to promote the research and novel therapeutic development for the treatment of rare diseases.

The initiative aims to provide high-quality genetically engineered mouse models (GEMMs) for previously underfunded biomedical research areas at the minimum cost of the scientists by leveraging the technology platform available at GemPharmatech. Launched in 2020, “The GEMMs for Rare Disease Research Initiative” has generated 87 GEMMs, which are of great value in supporting biomedical research and novel drug research and develop- ment in this area.

Since most rare diseases are single gene mutations, this initiative currently focuses to the construction of single-gene GEMMs. GemPharmatech funds more than 85% of the cost associated with GEMM construction, while the awardee contributes no more than 2000 US dollars per GEMM (shipping not included). GemPharmatech plans to establish 20 rare disease models for overseas scientists in 2021.

GemPharmatech Co., Ltd. is a leading provider of research mouse models and services. Its global headquarter is located in Nanjing, China. The Company is specialized in generating mouse models using cutting-edge gene editing technologies with a large collection of conditional knockout and knockout mice, humanized mice, immune deficient mice and germfree mice. GemPharmatech provides a one-stop solution in model customization, breeding, phenotyping, and pharmacology services to meet all preclinical research needs.

Application Procedure

  1. Applicants register and submit the application form to GemPharmatech by emailing by September 30th, 2021
  2. GemPharmatech evaluates and scores the proposals. Winning projects will be selected according to their scores.
  3. GemPharmatech informs the awardees before October 31st, 2021.
  4. Awardees sign the contract and complete the payment.
  5. GemPharmatech creates and delivers the GEMMs.

GEMMs generated through this initiative belong to GemPharmatech. A one-year protection period will be in place following model generation. Term details will be provided in the contract.